

### This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Cancer	IL-15; CD40	<p>Studies in mice suggest that IL-15 in combination with an anti-CD40 antibody could help treat cancer. In mouse models of colon cancer, combination therapy with murine IL-15 and an antibody that agonized CD40 significantly prolonged survival compared with that seen using either agent alone (<math>p &lt; 0.001</math>). Next steps include Phase I testing of IL-15 monotherapy to treat patients with melanoma or renal cell carcinoma (RCC) before proceeding to clinical trials of the combination therapy.</p> <p>Dacetuzumab (SGN-40), a humanized mAb against CD40 from Seattle Genetics Inc. and Roche's Genentech Inc. unit, is in Phase II testing to treat relapsed or refractory diffuse large B cell lymphoma (DLBCL) and is in Phase I testing to treat multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL).</p> <p><b>SciBX 2(17); doi:10.1038/scibx.2009.696</b>  <b>Published online April 30, 2009</b></p>	Unpatented; unlicensed	<p>Zhang, M. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online April 22, 2009;  doi:10.1073/pnas.0902637106  <b>Contact:</b> Thomas A. Waldmann,  National Cancer Institute,  Bethesda, Md.  e-mail:  <a href="mailto:tawald@helix.nih.gov">tawald@helix.nih.gov</a></p>